Company profile for Lycia Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic im...
We are building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Greater San Diego Area, West Coast, Western US
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/02/11/3024420/0/en/Lycia-Therapeutics-Announces-the-Appointment-of-Chin-Lee-MD-MPH-as-Chief-Medical-Officer-and-Reveals-Immunology-Pipeline.html

GLOBENEWSWIRE
12 Feb 2025

https://www.globenewswire.com/news-release/2024/05/13/2880276/0/en/Lycia-Therapeutics-Completes-106-6-Million-Series-C-Financing-to-Advance-Pipeline-of-LYTAC-Extracellular-Protein-Degraders-to-the-Clinic.html

GLOBENEWSWIRE
13 May 2024

https://lyciatx.com/lycia-therapeutics-completes-106-6-million-series-c-financing-to-advance-pipeline-of-lytac-extracellular-protein-degraders-to-the-clinic/

PRESS RELEASE
13 May 2024

https://www.globenewswire.com/news-release/2023/06/05/2681828/0/en/Lycia-Therapeutics-to-Present-at-Jefferies-Healthcare-Conference.html

GLOBENEWSWIRE
05 Jun 2023

https://www.globenewswire.com/news-release/2022/10/05/2528980/0/en/Lycia-Therapeutics-Founder-Dr-Carolyn-Bertozzi-Awarded-2022-Nobel-Prize-in-Chemistry.html

GLOBENEWSWIRE
05 Oct 2022

https://www.globenewswire.com/news-release/2022/02/28/2392954/0/en/Lycia-Therapeutics-Strengthens-Leadership-Team-with-Appointment-of-Steve-Staben-Ph-D-as-Chief-Scientific-Officer.html

GLOBENEWSWIRE
28 Feb 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty